PMID- 28662502
OWN - NLM
STAT- MEDLINE
DCOM- 20171107
LR  - 20190212
IS  - 1421-9778 (Electronic)
IS  - 1015-8987 (Linking)
VI  - 42
IP  - 3
DP  - 2017
TI  - MicroRNA-133b Ameliorates Allergic Inflammation and Symptom in Murine Model of 
      Allergic Rhinitis by Targeting Nlrp3.
PG  - 901-912
LID - 10.1159/000478645 [doi]
AB  - BACKGROUND: Emerging evidences indicate that post-transcriptional regulation by 
      microRNAs is critical in allergic rhinitis (AR) pathogenesis. MircroRNA-133b 
      (miR-133b) was recently suggested as a potential predictor of AR. However, the in 
      vivo effect of miR-133b on AR is unclear. METHODS: AR model was established in 
      BALB/c mice by intraperitoneal sensitization and intranasal challenge with 
      ovalbumin (OVA). MiR-133b agomir was then intranasally administrated to mice 
      after OVA challenge for another 7 days. The symptom of nasal rubbing and sneezing 
      were recorded after the last OVA challenge. Nasal mucosa tissues and serum were 
      collected. MiR-133b expression, serum OVA-specific immunoglobulin E (IgE) 
      concentration, proinflammatory cytokines (TNF-alpha, IL-4, IL-5, IL-10 and IFN-gamma) 
      levels, and Nlrp3 inflammasome activation were measured by RT-PCR, ELISA, western 
      blotting or immunohistochemistry, respectively. Histopathologic changes were 
      evaluated using hematoxylin and eosin and Sirius red staining. The luciferase 
      activity and protein expression of Nlrp3 were also determined. RESULTS: MiR-133b 
      expression was significantly decreased in nasal mucosa of AR mice, which was 
      restored by nasal administration with miR-133b agomir. Upregulation of miR-133b 
      markedly reduced the concentration of OVA-specific IgE, the frequencies of nasal 
      rubbing and sneezing, and the levels of cytokines (TNF-alpha, IL-4, IL-5 and IFN-gamma). 
      Levels of IL-4, IL-5, IL-10 and IFN-gamma produced by cervical lymph node cells were 
      significantly lowered in miR-133b agomir-treated mice. Moreover, miR-133b also 
      appeared to strongly attenuate pathological alterations and eosinophils and mast 
      cells infiltration in nasal mucosa. Notably, we demonstrated for the first time 
      that miR-133b negatively regulated Nlrp3 expression through binding with the 3' 
      untranslated region of Nlrp3. Consequently, infection of miR-133b in nasal mucosa 
      remarkably suppressed the Nlrp3 inflammasome activation, as evidenced by reduced 
      Nlrp3, Caspase-1, ASC, IL-18 and IL-1 expressions. CONCLUSION: MiR-133b 
      alleviates allergic symptom in AR mice by inhibition of Nlrp3 
      inflammasome-meditated inflammation. These findings provide us an insight into 
      the potential role of miR-133b in relation to AR treatment.
CI  - (c) 2017 The Author(s). Published by S. Karger AG, Basel.
FAU - Xiao, Lifeng
AU  - Xiao L
FAU - Jiang, Li
AU  - Jiang L
FAU - Hu, Qi
AU  - Hu Q
FAU - Li, Yuru
AU  - Li Y
LA  - eng
PT  - Journal Article
DEP - 20170626
PL  - Germany
TA  - Cell Physiol Biochem
JT  - Cellular physiology and biochemistry : international journal of experimental 
      cellular physiology, biochemistry, and pharmacology
JID - 9113221
RN  - 0 (Cytokines)
RN  - 0 (MicroRNAs)
RN  - 0 (Mirn133 microRNA, mouse)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
RN  - 0 (Nlrp3 protein, mouse)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Animals
MH  - Cytokines/blood
MH  - Disease Models, Animal
MH  - Down-Regulation
MH  - Genetic Therapy
MH  - HEK293 Cells
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Inflammation/blood/complications/genetics/therapy
MH  - Mice, Inbred BALB C
MH  - MicroRNAs/*genetics/*therapeutic use
MH  - NLR Family, Pyrin Domain-Containing 3 Protein/*genetics
MH  - Rhinitis, Allergic/blood/complications/*genetics/*therapy
MH  - Up-Regulation
OTO - NOTNLM
OT  - Allergic rhinitis
OT  - Inflammation
OT  - Nlrp3 inflammasome
OT  - microRNA-133b
EDAT- 2017/07/01 06:00
MHDA- 2017/11/08 06:00
CRDT- 2017/06/30 06:00
PHST- 2017/02/15 00:00 [received]
PHST- 2017/04/11 00:00 [accepted]
PHST- 2017/07/01 06:00 [pubmed]
PHST- 2017/11/08 06:00 [medline]
PHST- 2017/06/30 06:00 [entrez]
AID - 000478645 [pii]
AID - 10.1159/000478645 [doi]
PST - ppublish
SO  - Cell Physiol Biochem. 2017;42(3):901-912. doi: 10.1159/000478645. Epub 2017 Jun 
      26.